- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
High-alert therapy area: Rare disease products operate in a high-scrutiny environment — small trial populations, named patient use and patient advocacy group activity create compliance risks that standard frameworks do not always anticipate.
Promoting GLP-1 medicines beyond their licensed indication — or allowing third parties to do so — is the single largest source of complaints. Includes social media, influencer content and patient group materials.
Head-to-head efficacy comparisons between GLP-1 agents without robust data, or claiming "best in class" outcomes, have attracted multiple PMCPA rulings since 2022.
Posts about obesity as a disease that are seen as disguised brand promotion — particularly where product-specific hashtags or links are present — are a growing source of complaints.
Statements about NICE approval, NHS commissioning status or formulary listing must be current, accurate and not create an implication of superiority over alternatives.
Funding, content approval and disclosure requirements for patient advocacy groups are frequently mishandled in the obesity space given the level of patient advocacy activity.
Obesity trials often involve multiple endpoints and doses. Cherry-picking data or promoting trial results before licence extension is a significant risk.
Built specifically for pharma teams working in the rare diseases space — not generic compliance content repurposed for your therapy area.
The pack includes expert walkthroughs of all relevant PMCPA adjudications in the obesity space. Here are three landmark cases.
The pack includes all relevant obesity PMCPA cases with video walkthroughs, expert commentary and quiz questions.
MSLs and medical advisors interacting with HCPs on GLP-1 data, publications and off-label requests
Sales reps and marketing managers responsible for promotional materials and CRM communications
HEOR and market access teams making NHS/NICE claims in promotional and non-promotional materials
Regulatory affairs and compliance officers signing off obesity materials and providing guidance to teams
Speak to us about the Obesity Compliance Pack. Tell us your team size and therapy area focus and we'll put together the right package.
Looking for more therapy areas? Contact us about upcoming packs →
All 2,000+ PMCPA cases. Video. Podcast. Quiz. 5 points per case. The only case library of its kind in the UK.
Structured e-learning across 14 modules covering the ABPI Code 2024 in full. Role-based paths for sales, MSLs, medical and commercial.
Bespoke support for qualified persons and final signatories — particularly valuable for lean compliance teams in GLP-1 product launches.
One real case. One key lesson. Every week — free.